• Something wrong with this record ?

Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression

M. Petráš, V. Dvořák, D. Lomozová, R. Máčalík, S. Neradová, P. Dlouhý, J. Malinová, J. Rosina, IK. Lesná

. 2023 ; 99 (8) : 561-570. [pub] 20230808

Language English Country England, Great Britain

Document type Meta-Analysis, Systematic Review, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000524

OBJECTIVE: The main aim was to determine the overall vaccine effectiveness (VE) against recurrent cervical intraepithelial neoplasia grade 2 or worse (CIN2+) including specific VE associated with timing of human papillomavirus (HPV) vaccination using data from published studies. DESIGN: Meta-analysis and meta-regression. DATA SOURCES: A computerised literature search was undertaken using the MEDLINE, EMBASE, International Pharmaceutical Abstracts, Derwent Drug File, ProQuest Science and Technology, Cochrane and MedRxiv databases. To be eligible, the studies, with no language restrictions, had to be published between 1 January 2001 and 25 May 2023. REVIEW METHODS: Included were studies with an unvaccinated reference group that assessed CIN2+ recurrence irrespective of the HPV genotype in women undergoing conisation provided. The present study was carried out in compliance with the Preferred Reporting Items for Systematic Review and Meta-Analyses and Meta-analysis Of Observational Studies in Epidemiology guidelines. The risk of study bias was assessed using the Newcastle-Ottawa Quality Assessment Scale. The Grading of Recommendations Assessment, Development, and Evaluation guidelines were used to assess the strength of evidence for the primary outcome. Data synthesis was conducted using meta-analysis and meta-regression. RESULTS: Out of a total of 14 322 publications, 20 studies with a total of 21 estimates were included. The overall VE against recurrent CIN2+ irrespective of the HPV genotype achieved 69.5% (95% CI: 54.7% to 79.5%). While the HPV vaccine valency, follow-up duration, type of study including its risk of bias had no effect on VE, the highest VE of 78.1% (95% CI: 68.7% to 84.7%) was reported for women receiving their first dose not earlier than the day of excision. This outcome was supported by additional analyses and a VE prediction interval ranging from 67.1% to 85.4%. CONCLUSIONS: The outcome of this meta-analysis and meta-regression convincingly showed the beneficial effect of post-excisional HPV vaccination against CIN2+ recurrence. Studies published to date have been unable to determine whether or not vaccination, completed or initiated before conisation, would be associated with more favourable results. PROSPERO REGISTRATION NUMBER: CRD42022353530.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000524
003      
CZ-PrNML
005      
20240828143202.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/sextrans-2023-055793 $2 doi
035    __
$a (PubMed)37553234
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Petráš, Marek $u Department of Epidemiology and Biostatistics, Charles University, Prague, Czech Republic marek.petras@lf3.cuni.cz $1 https://orcid.org/0000000329131736
245    10
$a Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression / $c M. Petráš, V. Dvořák, D. Lomozová, R. Máčalík, S. Neradová, P. Dlouhý, J. Malinová, J. Rosina, IK. Lesná
520    9_
$a OBJECTIVE: The main aim was to determine the overall vaccine effectiveness (VE) against recurrent cervical intraepithelial neoplasia grade 2 or worse (CIN2+) including specific VE associated with timing of human papillomavirus (HPV) vaccination using data from published studies. DESIGN: Meta-analysis and meta-regression. DATA SOURCES: A computerised literature search was undertaken using the MEDLINE, EMBASE, International Pharmaceutical Abstracts, Derwent Drug File, ProQuest Science and Technology, Cochrane and MedRxiv databases. To be eligible, the studies, with no language restrictions, had to be published between 1 January 2001 and 25 May 2023. REVIEW METHODS: Included were studies with an unvaccinated reference group that assessed CIN2+ recurrence irrespective of the HPV genotype in women undergoing conisation provided. The present study was carried out in compliance with the Preferred Reporting Items for Systematic Review and Meta-Analyses and Meta-analysis Of Observational Studies in Epidemiology guidelines. The risk of study bias was assessed using the Newcastle-Ottawa Quality Assessment Scale. The Grading of Recommendations Assessment, Development, and Evaluation guidelines were used to assess the strength of evidence for the primary outcome. Data synthesis was conducted using meta-analysis and meta-regression. RESULTS: Out of a total of 14 322 publications, 20 studies with a total of 21 estimates were included. The overall VE against recurrent CIN2+ irrespective of the HPV genotype achieved 69.5% (95% CI: 54.7% to 79.5%). While the HPV vaccine valency, follow-up duration, type of study including its risk of bias had no effect on VE, the highest VE of 78.1% (95% CI: 68.7% to 84.7%) was reported for women receiving their first dose not earlier than the day of excision. This outcome was supported by additional analyses and a VE prediction interval ranging from 67.1% to 85.4%. CONCLUSIONS: The outcome of this meta-analysis and meta-regression convincingly showed the beneficial effect of post-excisional HPV vaccination against CIN2+ recurrence. Studies published to date have been unable to determine whether or not vaccination, completed or initiated before conisation, would be associated with more favourable results. PROSPERO REGISTRATION NUMBER: CRD42022353530.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory děložního čípku $x prevence a kontrola $x chirurgie $7 D002583
650    12
$a infekce papilomavirem $7 D030361
650    12
$a dysplazie děložního hrdla $7 D002578
650    _2
$a vakcinace $7 D014611
650    12
$a vakcíny proti papilomavirům $7 D053918
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořák, Vladimír, $d 1961- $7 xx0062700 $u Center of Ambulatory Gynecology and Primary Care, Brno, Czech Republic
700    1_
$a Lomozová, Danuše $u Department of Epidemiology and Biostatistics, Charles University, Prague, Czech Republic
700    1_
$a Máčalík, Roman $u Department of Epidemiology and Biostatistics, Charles University, Prague, Czech Republic
700    1_
$a Neradová, Sylva $u Department of Epidemiology and Biostatistics, Charles University, Prague, Czech Republic
700    1_
$a Dlouhý, Pavel $u Department of Hygiene, Charles University, Prague, Czech Republic
700    1_
$a Malinová, Jana $u Královské Vinohrady University Hospital, Prague, Czech Republic
700    1_
$a Rosina, Jozef $u Department of Medical Biophysics and Medical Informatics, Charles University, Prague, Czech Republic $u Department of Health Care and Population Protection, Ceské vysoké ucení technické v Praze Fakulta biomedicinského inzenyrstvi, Kladno, Czech Republic
700    1_
$a Lesná, Ivana Králová $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Anesthesia, Charles University First Faculty of Medicine, Prague, Czech Republic
773    0_
$w MED00010890 $t Sexually transmitted infections $x 1472-3263 $g Roč. 99, č. 8 (2023), s. 561-570
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37553234 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240828143158 $b ABA008
999    __
$a ok $b bmc $g 2049276 $s 1210218
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 99 $c 8 $d 561-570 $e 20230808 $i 1472-3263 $m Sexually transmitted infections $n Sex Transm Infect $x MED00010890
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options